Lexaria reports promising drug delivery study results
KELOWNA, BC - Lexaria Bioscience Corp. (NASDAQ:LEXX), a leader in drug delivery platforms with a market capitalization of $31.77 million, has announced significant advancements in its DehydraTECH ...
Lexaria Releases Annual Letter from the CEO
Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.
How to Play NVO Stock After New Drug's Success in Obesity Study
The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...
Zacks Small Cap Research on MSN3d
LEXX: IRB Approval Clears Way for GLP-1 Study #5
LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...
Creative Counting Can’t Fix The Inflation Reduction Act's Flaws
Millions of Part D patients who rely on price-controlled drugs will see their out-of-pocket medication costs increase.